+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Could changes in adiponectin drive the effect of statins on the risk of new-onset diabetes? The case of pitavastatin



Could changes in adiponectin drive the effect of statins on the risk of new-onset diabetes? The case of pitavastatin



Atherosclerosis. Supplements 16: 1-27



Statins represent the elective lipid-lowering strategy in hyperlipidemic and high cardiovascular-risk patients. Despite excellent safety and tolerability, reversible muscle-related and dose-dependent adverse events may decrease a patient's compliance. Large meta-analyses, post-hoc and genetic studies showed that statins might increase the risk of new-onset diabetes (NOD), particularly in insulin-resistant, obese, old patients. Race, gender, concomitant medication, dose and treatment duration may also contribute to this effect. Based on this evidence, to warn against the possibility of statin-induced NOD or worsening glycemic control in patients with already established diabetes, FDA and EMA changed the labels of all the available statins in the USA and Europe. Recent meta-analyses and retrospective studies demonstrated that statins' diabetogenicity is a dose-related class effect, but the mechanism(s) is not understood. Among statins, only pravastatin and pitavastatin do not deteriorate glycemic parameters in patients with and without type 2 diabetes mellitus. Interestingly, available data, obtained in small-scale, retrospective or single-center clinical studies, document that pitavastatin, while ameliorating lipid profile, seems protective against NOD. Beyond differences in pharmacokinetics between pitavastatin and the other statins (higher oral bioavailability, lower hepatic uptake), its consistent increases in plasma adiponectin documented in clinical studies may be causally connected with its effect on glucose metabolism. Adiponectin is a protein with antiatherosclerotic, anti-inflammatory and antidiabetogenic properties exerted on liver, skeletal muscle, adipose tissue and pancreatic beta cells. Further studies are required to confirm this unique property of pitavastatin and to understand the mechanism(s) leading to this effect.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 057529656

Download citation: RISBibTeXText

PMID: 25575403

DOI: 10.1016/s1567-5688(14)70002-9


Related references

Effect of high-dose pitavastatin on glucose homeostasis in patients at elevated risk of new-onset diabetes: insights from the CAPITAIN and PREVAIL-US studies. Current Medical Research and Opinion 30(5): 775-784, 2014

Use of antidepressants and statins and short-term risk of new-onset diabetes among high risk adults. Diabetes Research and Clinical Practice 105(2): 251-260, 2014

The long-term effect of statins on the risk of new-onset diabetes mellitus in elderly Taiwanese patients with hypertension and dyslipidaemia: a retrospective longitudinal cohort study. Drugs and Aging 29(1): 45-51, 2012

Statins and risk of new-onset diabetes mellitus. Circulation 126(18): E282-E284, 2012

Is the risk of new-onset diabetes by statins associated with diet adherence?. International Journal of Cardiology 166(1): 277, 2013

Statins and new onset of diabetes: which one outweighs risk or benefit?. Postgraduate Medicine 130(1): 146, 2018

Research progress on statins use and the risk of new onset diabetes. Zhonghua Xin Xue Guan Bing Za Zhi 44(5): 456-457, 2016

Effect of Pitavastatin Compared with Atorvastatin andRosuvastatin on New-Onset Diabetes Mellitus in PatientsWith Acute Myocardial Infarction. American Journal of Cardiology 122(6): 922-928, 2018

Does coenzyme Q10 play a role in the risk of new-onset diabetes due to statins?. International Journal of Cardiology 225: 260-261, 2016

Statins and the risk of new-onset diabetes: a review of recent evidence. Current Opinion in Lipidology 22(6): 460-466, 2011

Adiponectin and risk of new-onset diabetes mellitus after kidney transplantation. Transplantation 78(1): 26-30, 2004

Statins and new-onset diabetes mellitus - a risk lacking in familial hypercholesterolaemia. Journal of Internal Medicine 279(4): 358-361, 2016

Statins and risk of new-onset diabetes: A meta-analysis of observational studies. Nutrition, Metabolism and Cardiovascular Diseases 27(1): E29-E30, 2017

Effect of Statins on Glycemic Status and Plasma Adiponectin Concentrations in Patients with Type 2 Diabetes Mellitus and Hypercholesterolemia. Yakugaku Zasshi 139(5): 807-815, 2019

Statins and risk of new-onset diabetes mellitus: is there a rationale for individualized statin therapy?. American Journal of Cardiovascular Drugs 14(2): 79-87, 2014